SG
ARTL icon

StoneX Group’s Artelo Biosciences ARTL Stock Holding History

StoneX Group’s Portfolio ARTL Stock Details ARTL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$14.7K Buy
+1,378
New +$35.5K ﹤0.01% 1337
2022
Q3 		– Sell
-6
Closed -$4.75K – 566
2022
Q2 		$4.75K Buy
+6
New +$5.31K ﹤0.01% 691

Other funds holding ARTL

Jane Street
Jane Street New York $1.21T AUM 78.12% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
TRCT
Tower Research Capital (TRC) New York $4.08B AUM 58.77% 1-Year Est. Return
Vanguard Fiduciary Trust
Vanguard Fiduciary Trust Malvern, Pennsylvania $454B AUM
UBS Group
UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return
RIL
Rothschild Investment LLC Chicago, Illinois $2.68B AUM 34.39% 1-Year Est. Return
TWC
TD Waterhouse Canada Toronto, Ontario, Canada $38B AUM 39.14% 1-Year Est. Return
DB
Danske Bank Copenhagen K, Denmark $50.6B AUM 42.84% 1-Year Est. Return

StoneX Group's ARTL Position: Q2 2026 in Review

StoneX Group opened a new position in Artelo Biosciences (ARTL) in Q2 2026: 1,378 shares worth $14.7K. The stake represents ﹤0.01% of the portfolio and ranks #1337 among its holdings. This is a return to the name: StoneX Group previously reported a position in ARTL as recently as Q2 2022.

StoneX Group first reported a position in ARTL in Q2 2022 and has held it in 2 quarters since. 7 funds tracked by Wall St. Rank hold ARTL as of Q2 2026.

  • StoneX Group held 1,378 shares of Artelo Biosciences worth $14.7K as of Q2 2026.
  • Artelo Biosciences was a new StoneX Group position in Q2 2026.
  • Artelo Biosciences made up ﹤0.01% of StoneX Group's portfolio in Q2 2026, its #1337 holding.
  • StoneX Group first reported a position in Artelo Biosciences in Q2 2022 and has held it in 2 quarters since.
  • 7 funds tracked by Wall St. Rank held Artelo Biosciences as of Q2 2026.

Based on StoneX Group's 13F filing for Q2 2026, filed 12 Aug 2026.